Clinical trial · Interventional
Decision Aids for Tamoxifen Treatment in Breast Cancer Patients
Utilization of Decision Aids for Tamoxifen Treatment in Breast Cancer Patients: A Randomized Controlled Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an educational intervention study for breast cancer patients who undergo tamoxifen treatment. The purpose of the study is to assess the impact of decision aids (DA) on the patients' decision-making process, compliance on drug, and knowledge regarding tamoxifen treatment. Patients will randomly assign to DA group or conventional group. Both groups will have baseline questionnaire surveys before starting tamoxifen treatment, and 4 weeks later follow-up questionnaire surveys.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Decision aids (tamoxifen-related educational materials in brochure or mobile app) | Behavioral | — | UNRESOLVED |
| tamoxifen | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Decision aids
- interventionNames
- Behavioral: Decision aids (tamoxifen-related educational materials in brochure or mobile app)
- Drug: tamoxifen
- type
- NO_INTERVENTION
- label
- usual care
Primary outcomes (1)
- measure
- Change in Knowledge of Tamoxifen Scale
- timeFrame
- baseline, 4weeks later
Secondary outcomes (4)
- measure
- Decisional Conflict Scale
- timeFrame
- baseline, 4weeks later
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer patients who are recommended to undergo tamoxifen treatment in National Cancer Center, Korea * \- Age at least 18 years and more Exclusion Criteria: * Age under 18 years * Inability to read or speak Korean * Disagree to provide a written informed consent
References
Publications (0)
Data not yet available